Acalabrutinib is a second-generation, highly selective Bruton's tyrosine kinase (BTK) inhibitor used in chronic lymphocytic leukaemia and mantle cell lymphoma, designed to minimise off-target kinase inhibition seen with earlier BTK inhibitors. Its targeted mechanism and oncology indication call for stringent impurity control. Simson Pharma's Acalabrutinib reference standard and related impurities support stability-indicating assay development.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Acalabrutinib Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.